Trending in Altmetric
This article is in the top 10% of similar research outputs scored by Altmetric,
a service which tracks the online attention articles have received.
McMaster PLUS Selected
This article has been identified as especially clinically relevant or newsworthy by at least 3
practicing clinicians and of high scientific quality by expert researchers
as a part of the McMaster PLUS article rating service.
DescriptorName: Diabetes Mellitus, Type2... glucagon-like peptide 1 analogue, with placebo in patients with type2diabetes and high cardiovascular risk who were receiving usual care, we ... term effects of liraglutide on renal outcomes in patients with type2diabetes are unknown AbstractText: We report the prespecified secondary renal outcomes ...
... predict rapid decline in estimated glomerular filtration rate (eGFR) in type2diabetes AbstractText: Mass spectrometry was used to measure baseline biomarkers in ... patients (mean age 67.0 years, 51.9% males) from the Fremantle Diabetes Study Phase II... in renal function independently of recognized clinical risk factors in type2diabetes.
Endocrine Disorders (5), Kidney Disease (1) Diabetes Mellitus, Type 2 (3), Diabetes Mellitus (2), Chronic Kidney Diseases (1), more mentions
Although type2diabetes is a strong risk factor for cardiovascular disease and mortality ... according to baseline disease status, as follows: none (reference group); diabetes only; diabetes and stroke; diabetes and myocardial infarction (MI); and diabetes, stroke, and MI ... and markedly increased with more cardiometabolic comorbidities.Young Asians with type2diabetes, especially those with cardiovascular comorbidity, did not live as long ...
Endocrine Disorders (11), Cardiovascular Diseases (2) Diabetes Mellitus (8), Diabetes Mellitus, Type 2 (3), Cardiovascular Diseases (2), more mentions
... our study was to compare the acute effect of soluble fiber intake from foods or supplements after a common meal on postprandial plasma glucose and plasma insulin in patients with type2diabetes (T2D).Design: A randomized crossover clinical trial was conducted in patients with T2D... Keyword: type2diabetes.
Endocrine Disorders (3), Anti-Obesity and Weight Loss (1) Diabetes Mellitus, Type 2 (3), more mentions
... β-cell function is a prerequisite for the development of type2diabetes, yet the level of β-cell function in individuals at ... are required in additional clinical cohorts and in patients with type2diabetes, but these results identify novel pathways and biomarkers that may ... future decline, allowing more targeted efforts to prevent and intercept type2diabetes.
Endocrine Disorders (5), Cardiovascular Diseases (1), Anti-Obesity and Weight Loss (1) Diabetes Mellitus, Type 2 (5), Insulin Sensitivity (2), Cardiovascular Diseases (1), more mentions
Obesity is associated with an increased risk of type2diabetes and cardiovascular complications... adipose tissue (VAT) in obese subjects with prediabetes or early type2diabetes.Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type2diabetes, were randomized to liraglutide (1.8 mg/d) or lifestyle counseling ...
Anti-Obesity and Weight Loss (11), Endocrine Disorders (4) Diabetes Mellitus, Type 2 (4), Prediabetic State (3), Obesity (1), more mentions
... 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type2diabetes and established cardiovascular disease in the EMPA-REG OUTCOME(®) trial ... the effects of empagliflozin on clinical outcomes in patients with type2diabetes, established cardiovascular disease and chronic kidney disease. Methods -Patients with type2diabetes, established cardiovascular disease and estimated glomerular filtration rate (eGFR) ≥30 ...
... weekly treatment with exenatide to usual care in patients with type2diabetes are unknown. Methods We randomly assigned patients with type2diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections ... Conclusions Among patients with type2diabetes with or without previous cardiovascular disease, the incidence of major ...
AbstractText: To assess primary care physicians' (PCPs) knowledge of type2diabetes screening guidelines (American Diabetes Association (ADA) and 2008 US Preventive Services Task Force (USPSTF ... reported adherence and actual practice, and how often PCPs recommended diabetes prevention and self-management education programs (DPP/DSME) AbstractText: An ... 45% and 67% of their newly diagnosed patients with pre-diabetes and diabetes, respectively AbstractText: Findings show disconnect between PCPs' perceptions of adherence ...
Endocrine Disorders (7) Diabetes Mellitus (5), Diabetes Mellitus, Type 2 (2), more mentions
Abstract: Type2diabetes (T2D) has many cardiovascular complications, including a thrombotic propensity... Given the prevalence of amyloid formation in the sequelae of diabetes, this opens up novel strategies for both the prevention and treatment of T2D.
Endocrine Disorders (2) Diabetes Mellitus, Type 2 (1), Thrombophilia (1), Diabetes Mellitus (1), more mentions
... Diet is frequently associated with both the development and prevention of type2diabetes (T2D), but there is a lack of objective tools for assessing ... tolerance (NGT; n = 190), impaired glucose tolerance (IGT; n = 209), and diabetes (n = 230... 167 for NGT, n = 174 for IGT, and n = 159 for diabetes.
Endocrine Disorders (4), Cardiovascular Diseases (1) Diabetes Mellitus, Type 2 (2), Diabetes Mellitus (2), Cardiovascular Diseases (1), more mentions
Glycated hemoglobin (HbA1c) is used to diagnose type2diabetes (T2D) and assess glycemic control in patients with diabetes... expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance.
Endocrine Disorders (5) Glucosephosphate Dehydrogenase Deficiency (3), Diabetes Mellitus (3), Diabetes Mellitus, Type 2 (2), more mentions
Abstract: To evaluate the shared genetic etiology of type2diabetes (T2D) and coronary heart disease (CHD), we conducted a genome-wide, multi-ancestry study of genetic variation for both diseases in up to 265,678 subjects for T2D and 260,365 subjects for CHD. We identify 16 previously unreported loci for T2D and 1 locus for CHD, including a ...
Cardiovascular Diseases (2), Endocrine Disorders (2) Coronary Disease (2), Diabetes Mellitus, Type 2 (2), more mentions
... Hypertrophic remodelling of white adipose tissues is associated with lean organs overexposure to circulating triglycerides (TG) and non-esterified fatty acids (NEFA), ultimately leading to insulin resistance. Bariatric surgery promotes type2diabetes (T2D) remission by a succession of weight-loss dependent and independent mechanisms. However, the longitudinal contribution of adipocytes size reduction and fatty acid metabolic handling remain unknown.
Anti-Obesity and Weight Loss (4), Endocrine Disorders (3) Diabetes Mellitus, Type 2 (2), Hypertriglyceridemia (1), Insulin Sensitivity (1), more mentions
Abstract: Canagliflozin (Invokana(®)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type2diabetes (T2D. Canagliflozin lowers blood glucose levels independently of insulin, with the inhibition of SGLT2 reducing renal reabsorption of glucose and increasing excretion of glucose in the urine.
Endocrine Disorders (2), Urology (1) Diabetes Mellitus, Type 2 (2), Urinary Tract Infections (1), more mentions